PARP inhibitors continue to impress in the ovarian cancer space, as findings from the recent phase 3 SOLO-1 trial showed that Lynparza (olaparib) showed clinically-meaningful improvement in progression-free survival (PFS) when used in the first-line maintenance setting.
Because little is known about the effect of patients' sex on the efficacy of immune checkpoint inhibitors as cancer treatments, the researchers performed a systematic review and meta-analysis to determine the heterogeneity of immune checkpoint inhibitor efficacy between men and women.
Sometimes it pays to play the cancer card.
There are many signs and symptoms of breast cancer, although some of them aren't very well known. Early detection can help prevent more serious problems. Learn more about how to recognize and protect yourself.
What are the different types of immunotherapy and, importantly, what are fellow patients saying about them?
Moving from shock to action is hard, but it's critical to surviving cancer
At the end of life, patients and physicians both have their own goals when it comes to care and treatment; however, researchers from Case Western Reserve University and Flatiron Health have found that those goals are sometimes at odds with one another.
At the GI Cancer Patient Summit, a panel of caregivers drew upon personal experience to offer advice and discuss what more can be done for individuals in this role of the cancer journey.
Cancer can give writers a special edge.
We spoke with veteran journalist Neil Canavan about his book, A Cure Within: Scientists Unleashing the Immune System to Kill Cancer.
The FDA has approved the combination of the BRAF inhibitor Braftovi (encorafenib) and the MEK inhibitor Mektovi (binimetinib) for the treatment of patients with BRAF-mutant unresectable or metastatic melanoma, as detected by an FDA-approved test.
The Food and Drug Administration (FDA) has granted a priority review to a new drug application (NDA) for glasdegib to treat patients with previously untreated acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC), which is a type of chemotherapy, according to Pfizer, the manufacturer of the drug.
As we survive cancer, people often turn to us for advice. Listening mindfully as we also share personal tips can help others in their cancer journeys. The list of tips can only grow from survivor to survivor. What do you have to share?
These discussions should include information about the cancer itself, as well as treatment options, side effects, prognosis, and most importantly, the patient’s values.
Four ways of helping cancer survivors deal with anxiety and depression.
Checkpoint inhibitors — immunotherapy drugs that are improving the treatment landscape for many patients across the spectrum of cancers — are relatively new. The science involved in finding and treating the patients most likely to respond to these drugs — without overlooking any or treating those who won’t benefit — is even newer.
A no-brainer bill about student loans for young adult cancer patients that I spent a day advocating for. You can help - read to the end!
We've known for over a century about rare patients who experience spontaneous regressions of cancer. We don’t have absolute proof, but, presumably, this occurs because their immune systems are able to rally and fight the disease.
Fear of cancer recurrence is a common issues survivors face. The struggle is real to keep it in its proper place. Read how one survivor sees the struggle.
Patients with mantle cell lymphoma (MCL) who were treated with Venclexta (venetoclax) showed a slight improvement in response rates compared with chemoimmunotherapy.
While JAK inhibitors have proven to be an effective treatment for patients with myelofibrosis, a type of myeloproliferative neoplasm (MPN), they may come with a severe downside – in particular, a 16-fold increase in the chance of developing a B-cell lymphoma, according to recent research published in the journal Blood.
The FDA has accepted a supplemental biologics license application (sBLA) for the use of Keytruda (pembrolizumab) as an adjuvant treatment for patients with resected, high-risk stage 3 melanoma, according to Merck (MSD), the manufacturer of the PD-1 inhibitor.
The FDA has granted a priority review to a supplemental new drug application (sNDA) Imbruvica (ibrutinib) for use in combination with Rituxan (rituximab) as a treatment option across all lines of therapy for patients with Waldenström macroglobulinemia.
An IBC patient reflects on her search for an alternative to conventional treatment.
There can be definite struggles for childhood cancer survivors, even many years later.
A recent review of data found that 79 percent of patients with ovarian cancer felt uncomfortable raising psychological and emotional concerns during their consultations.
Stand Up To Cancer’s “interception” trials tackle lung and pancreatic disease early, with the goal of preventing progression to advanced stages.
Palliative care doesn't mean giving up treatment, it means getting the support you need as a patient with metastatic cancer.
In the QUADRA study, treatment with Zejula (niraparib) demonstrated durable responses among women with relapsed or refractory ovarian cancer, regardless of BRCA mutation.
What to do when cancer isn't ruining your summer...
